| Outcome Measures: |
Primary: Change in 24-hour Sodium Excretion From Baseline to Start of Treatment, Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed., From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4) | Secondary: Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up, Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17)., From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)|Change in 24-hour Glucose Excretion From Baseline to Start of Treatment, Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4)., From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)|Change in 24-hour Glucose Excretion From Baseline to End of Treatment, Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14), From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)|Change in 24-hour Glucose Excretion From End of Treatment to Follow-up, Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17)., From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)|Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment, Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4), From baseline (Day -1) to start of treatment (Day 4)|Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment, Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13)., From baseline (Day -1) to end of treatment (Day 13)|Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up, Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18)., From end of treatment (Day 13) to end of follow-up (Day 18)|Change in Plasma Volume From Baseline to Start of Treatment, Change in plasma volume from baseline to start of treatment (Day 4)., From baseline (Day 1) to start of treatment (Day 4)|Change in Plasma Volume From Baseline to End of Treatment, Change in plasma volume from baseline to end of treatment (Day 14)., From baseline (Day 1) to end of treatment (Day 14)|Change in Plasma Volume From End of Treatment to End of Follow-up, Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18)., From end of treatment (Day 14) to end of follow-up (Day 18)|Change in Extracellular Volume From Baseline to Start of Treatment, Change in extracellular volume from baseline to start of treatment (Day 4)., From baseline (Day 1) to start of treatment (Day 4)|Change in Extracellular Volume From Baseline to End of Treatment, Change in extracellular volume from baseline to end of treatment (Day 14)., From baseline (Day 1) to end of treatment (Day 14)|Change in Extracellular Volume From End of Treatment to End of Follow-up, Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18)., From end of treatment (Day 14) to end of follow-up (Day 18)|Change in 24-hour Urine Albumin:Creatinine Ratio (UACR), Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14)., From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)|Pharmacokinetics of Dapagliflozin on Day 4 and Day 14, Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose), At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)|Number of Patients With AEs and SAEs, An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event., From Day 1 until Day 18 (Follow-up)
|
| Locations: |
Research Site, Almelo, 7609 PP, Netherlands|Research Site, Amsterdam, 1081 HV, Netherlands|Research Site, Stockholm, 14186, Sweden|Research Site, Örebro, 70185, Sweden
|
